PathoVax LLC

PathoVax is advancing a human papillomavirus (HPV) virus-like particle (VLP) technology developed at Johns Hopkins. Our lead patented vaccine, RGVax, is the first vaccine to target all 15 cancer-causing HPVs in a market with $2B+ annual revenues while offering the opportunity to be marketed as a pediatric vaccine to expand uptake. Current funding which includes an NCI contract worth $US5M provides an operating runway to IND approval in 2019, and we plan to complete our phase 1 human safety studies for strategic exits in 2021. Beyond this lead indication, HPV VLPs are robust carriers for novel antigens to induce targeted immune responses.